1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsDoD Melanoma Research Program Melanoma Academy Scholar Award is sponsored by Dept. of the Army -- USAMRAA. This award supports early-career melanoma investigators (within 7 years of first faculty appointment or equivalent) by integrating them into a virtual academy for intensive mentoring, national networking, collaborations, and peer support.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
DoD Melanoma, Melanoma Academy Scholar Award by Dept. of the Army -- USAMRAA | Atom Grants DoD Melanoma, Melanoma Academy Scholar Award DoD grant for early-career melanoma researchers to join a virtual academy, fostering collaboration and career growth with mentorship and up to $550K funding over 3 years. This grant is no longer accepting proposals Dept.
of the Army -- USAMRAA has archived this opportunity. Funder: Dept. of the Army -- USAMRAA Due Dates: September 10, 2025 (Pre-application/LOI) | October 1, 2025 (Full application) Funding Amounts: Up to $770,000 total costs per award (3 years max); approximately 2 awards expected Summary: Supports early-career independent investigators joining the Melanoma Academy to advance research and career development in melanoma.
Key Information: Applicants must be ≤7 years from first faculty appointment and designate a qualified Career Guide; clinical trials are not allowed. This opportunity seeks to add independent, early-career investigators ("Scholars") to the Department of Defense (DoD) Melanoma Research Program (MRP) Melanoma Academy.
The Academy is a virtual, multi-institutional network designed to foster collaboration, mentorship, and career development among melanoma researchers. This award supports both the Scholar’s research and career trajectory, emphasizing impactful research in melanoma and sustained professional growth through structured mentorship.
The program is designed for early-career investigators who wish to pursue research in melanoma, with the guidance of a senior Career Guide, and contribute to the advancement of the field. Projects must address at least one of the MRP’s FY25 focus areas: prevention/interception, rare melanomas, or survivorship. See the full grant listing
According to the current listing, eligibility includes: Unrestricted. Investigators must be within 7 years of their first faculty appointment or equivalent. Requires a Career Guide. Confirm the full requirements in the official notice before applying.
The current listing shows up to $770,000 over 3 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was September 22, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
DoD Melanoma Research Program Melanoma Academy Scholar Award is funded by Dept. of the Army -- USAMRAA. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged.Distinctive Features: The FY26 CTRA offers two funding levels:• Funding Level 1 to support smaller, less complex preclinical and/or clinical research.• Funding Level 2 to support larger, more complex preclinical and/or clinical research.The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories:• Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission.• Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed. Funding Opportunity Number: HT942526DMDRPCTRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $8.5M total program funding.
DoW Duchenne Muscular Dystrophy, Idea Development Award is sponsored by Dept. of the Army -- USAMRAA. Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation.
After SBIR reauthorization, the U.S. Army released five new small-business topics under Army FUZE — Ka-Band metamaterial radar, a Li-ion 6T battery open topic, in-transit-visibility blockchain, modular UAS payloads, and the xTech|Phantum prize competition. Awards run from $150K to $300K per Phase I. But the bigger story is the Army's shift from funding parts to funding whole systems. Here is what each topic funds and how to compete.
Read articleDARPA transferred its first autonomous-ready H-60Mx Black Hawk to the Army on March 20, capping a decade of ALIAS research. Now the same technology underpins an SBIR XL opportunity for small businesses building wildfire autonomy.
Read article